Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Cardiovascular Diseases × Liraglutide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 6 Obesity 4 Weight Loss 2 Sexual Infantilism 1 Prediabetic State 1 Pancreatic Neoplasms 1 Obesity, Abdominal 1 Metabolic Syndrome 1 Insulin Resistance 1 Inflammation 1 Infertility, Female 1 Infertility 1 Glucose Intolerance 1 Dyslipidemias 1 Diabetes Mellitus, Type 2 1 Craniopharyngioma 1 Combined Pituitary Hormone Deficiency 1 Cardiovascular Diseases 1

Interventions

Exercise 4 Cholecalciferol 4 Gonadotropin-Releasing Hormone 3 Blood Pressure 3 Atorvastatin 3 palbociclib 2 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2 acalabrutinib 2 Vitamin E 2 Social Determinants of Health 2 Rosuvastatin Calcium 2 Nutrition Assessment 2 Metformin 2 Geritol 2 Fish Oils 2 Fatty Acids, Omega-3 2 Ethanol 2 Educational Status 2 Diet, Mediterranean 2 Blood Specimen Collection 2 Aspirin 2 Absorptiometry, Photon 2 zanubrutinib 1 xinmailong 1 ribociclib 1 phosphoribosylformylglycinamidine synthetase 1 pembrolizumab 1 ibrutinib 1 glycidol 1 beta Carotene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02073929 2019-02-28

LIPT

Herlev Hospital

Phase 4 Completed

72 enrolled 18 charts

Cardiovascular Diseases, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡